# Antitussive Effects of FP01 Lozenges in Subjects With Cough Due to Upper Respiratory Tract Infection

> **NCT01597349** · PHASE2 · COMPLETED · sponsor: **Avalo Therapeutics, Inc.** · enrollment: 208 (actual)

## Conditions studied

- Acute Cough

## Interventions

- **DRUG:** FP01

## Key facts

- **NCT ID:** NCT01597349
- **Lead sponsor:** Avalo Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2012-09
- **Final completion:** 2012-09
- **Target enrollment:** 208 (ACTUAL)
- **Last updated:** 2014-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01597349

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01597349, "Antitussive Effects of FP01 Lozenges in Subjects With Cough Due to Upper Respiratory Tract Infection". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01597349. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*